Mylan NV Financial Indicators Patterns

MYL -- USA Stock  

Fiscal Quarter End: December 31, 2019  

You can employ fundamental analysis to find out if Mylan NV is mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We found thirty-six available fundamentals for Mylan NV which can be compared to its peers in the industry. To make sure the equity is not overpriced, please verify all Mylan NV fundamentals including its Price to Book, Current Ratio, Retained Earnings, as well as the relationship between Net Income and Price to Earnings To Growth . Given that Mylan NV has Number of Shares Shorted of 25.69 M, we recommend you check Mylan NV last-minute market performance to make sure the company can sustain itself down the road. Use Mylan NV to protect your portfolios against small markets fluctuations. The stock experiences somewhat bearish sentiment, but market may correct it shortly. Check odds of Mylan NV to be traded at $18.45 in 30 days.
51%51%

Chance of Financial Distress

Mylan NV has more than 51 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

Mylan NV Company Summary

Mylan NV competes with Eagle Pharmaceuticals, Flexion Therapeutics, Endo International, Elanco Animal, and Aurora Cannabis. Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter pharmaceutical products in North America, Europe, and internationally. The company was founded in 1961 and is based in Hatfield, the United Kingdom. Mylan NV operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 35000 people.

Mylan NV Book Value Per Share vs Price to Book

Mylan NV is regarded second in book value per share category among related companies. It is rated below average in price to book category among related companies fabricating about  0.05  of Price to Book per Book Value Per Share. The ratio of Book Value Per Share to Price to Book for Mylan NV is roughly  18.36 

Mylan NV Systematic Risk

The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Mylan NV correlated with the market. If Beta is less than 0 Mylan NV generally moves in the opposite direction as compared to the market. If Mylan NV Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Mylan NV is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Mylan NV is generally in the same direction as the market. If Beta > 1 Mylan NV moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

Mylan NV Thematic Clasifications

Obamacare Repeal Idea
Obamacare RepealView
Obamacare Idea
ObamacareView

Mylan NV December 9, 2019 Opportunity Range

Please see also Stocks Correlation. Please also try Equity Valuation module to check real value of public entities based on technical and fundamental data.
Search macroaxis.com